Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate if AC-084 is Safe, Its Fate in the Body as Well as Its Potential Effects on the Body in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent in the local language prior to any study-mandated procedure~* Healthy male subjects for Part A, healthy male and female subjects for Part B and Part C aged between 18 and 55 years (inclusive) at screening~* No clinically significant findings on physical examination at screening~* Body mass index (BMI) of 18.0 to 28.0 kg/m2 (inclusive) at screening~* CYP2C9 poor metabolizers (Part C)~Exclusion Criteria:~* History or clinical evidence of any disease and/or existence of any surgical or medical condition that might interfere with the absorption, distribution, metabolism or excretion of the study treatment (appendectomy and herniotomy allowed, cholecystectomy not allowed)~* Previous history of fainting, collapse, syncope, orthostatic hypotension, or vasovagal reactions~* Treatment or substances known to induce CYP enzyme drug metabolism within 30 days prior to first study treatment administration~* Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol~* Known allergic reactions or hypersensitivity to the study treatment or drugs of the same class, or any of their excipients~* For Part A and Part B, CYP2C9 poor metabolizers enrolled in a cohort to be dosed with single or multiple dose of 500 mg or higher of ACT-774312 (confirmed by genotyping before enrollment)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- AC-084, single ascending dose (Part A) (Type: EXPERIMENTAL): AC-084 administered at different single dose levels in a sequential manner, and in a maximum of 7 dose levels starting from 1 mg (number of cohorts and dose levels will depend on the safety and pharmacokinetic results of the previous cohort). Each dose level will be investigated in a new group of at least 8 healthy male subjects (6 on active drug and 2 on placebo)
- Placebo,single ascending dose (Part A) (Type: PLACEBO_COMPARATOR): Matched placebo administered as single ascending doses in parallel to AC-084
- AC-084, multiple ascending dose (Part B) (Type: EXPERIMENTAL): AC-084 administered in a twice daily (b.i.d.) dosing regimen at multiple dose levels. The starting dose will be between 1 and 30 mg and will be selected on the basis of the safety and pharmacokinetic results of the part A. Each dose level will be investigated in a new group of at least 8 healthy male subjects (6 on active drug and 2 on placebo)
- Placebo,multiple ascending dose (Part B) (Type: PLACEBO_COMPARATOR): Matched placebo administered as multiple ascending doses in parallel to AC-084
- AC-084, single dose (Part C) (Type: EXPERIMENTAL): Up to 6 subjects in part C will receive AC-084 administered at a single dose (foreseen to be 100 mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).